Catalyst Brief

← Calendar

Readoutin 14d

Exelixis — XL092

Phase 3 primary completion: Study of XL092 + Nivolumab vs Sunitinib in Subjects With Advanced or Metastatic Non-Clear Cell Renal Cell Carcinoma.

Date
Dec 2026
Type
Readout
Indication
Non-Clear Cell Renal Cell Carcinoma

Source ↗Add to calendar

Get told when this date moves

The weekly brief is free. Pro adds reminders 7 days and 1 day before.